Recombinant tissue plasminogen activator following paediatric cataract surgery

Br J Ophthalmol. 2000 Sep;84(9):983-6. doi: 10.1136/bjo.84.9.983.

Abstract

Background: The use of recombinant tissue plasminogen activator (r-TPA) has been advocated in the treatment of postsurgical fibrinous membrane formation following cataract surgery in adults. Its use in paediatric cases is not well documented.

Method: A retrospective review of paediatric cataract extractions performed at Moorfields Eye Hospital between 1 January 1997 and 4 April 1999 was carried out.

Results: Cataract extractions were performed in 37 patients, 22 in males 15 in females. Four (9.2%) underwent intracameral injection of 25 microg r-TPA. They were all females of Afro-Caribbean origin. The time to injection varied from 4-14 days, mean 7.2 days. Complete resolution of the fibrinous membrane was seen in all cases. There were no complications by the 3 month follow up.

Conclusion: r-TPA may be used safely and effectively at a dose of 25 microg for the treatment of severe fibrinous membranes following paediatric cataract extraction. It aided the visual recovery of the children and also allowed a reduced regimen of topical steroid therapy to be used postoperatively.

MeSH terms

  • Anterior Chamber / pathology*
  • Cataract Extraction / methods*
  • Child
  • Child, Preschool
  • Female
  • Fibrin / drug effects
  • Fibrinolytic Agents / administration & dosage*
  • Fibrosis / prevention & control
  • Humans
  • Infant
  • Male
  • Postoperative Complications / drug therapy*
  • Serine Endopeptidases / administration & dosage*
  • Tissue Plasminogen Activator / administration & dosage*
  • Visual Acuity / drug effects

Substances

  • Fibrinolytic Agents
  • Fibrin
  • Serine Endopeptidases
  • Tissue Plasminogen Activator